IL1B and myocardial infarction: Indeed, Ridker et al conducted a randomized double-blind trial enrolling 10,061 patients with a history of myocardial infarction and a high sensitivity C-reactive protein level of 2 mg or more per liter and showed that canakinumab, a neutralizing antibody for IL-1β, led to a significant lower rate of recurrent cardiovascular events in these patients (Ridker et al, 2017).